Philip J Rosenthal

List of Publications by Year
in descending order

265 papers	15,178 citations	15466 65 h-index	24915 109 g-index
275 all docs	275 docs citations	275 times ranked	11768 citing authors

#	Article	IF	Citations
1	Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malaria Journal, 2011, 10, 144.	0.8	663
2	Antimalarial drug discovery: efficacy models for compound screening. Nature Reviews Drug Discovery, 2004, 3, 509-520.	21.5	633
3	Chemical genetics of Plasmodium falciparum. Nature, 2010, 465, 311-315.	13.7	515
4	Characterization of Native and Recombinant Falcipain-2, a Principal Trophozoite Cysteine Protease and Essential Hemoglobinase ofPlasmodium falciparum. Journal of Biological Chemistry, 2000, 275, 29000-29010.	1.6	317
5	Artemisinin activity against<i>Plasmodium falciparum</i>requires hemoglobin uptake and digestion. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11405-11410.	3.3	293
6	Cysteine proteases of malaria parasites. International Journal for Parasitology, 2004, 34, 1489-1499.	1.3	281
7	Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4384-4389.	3.3	265
8	Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network. American Journal of Tropical Medicine and Hygiene, 2015, 93, 57-68.	0.6	250
9	Absence of Putative Artemisinin Resistance Mutations Among Plasmodium falciparum in Sub-Saharan Africa: A Molecular Epidemiologic Study. Journal of Infectious Diseases, 2015, 211, 680-688.	1.9	235
10	Vinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug Design. Journal of Biological Chemistry, 2009, 284, 25697-25703.	1.6	234
11	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal of Tropical Medicine and Hygiene, 2014, 91, 833-843.	0.6	204
12	Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochemical Journal, 2001, 360, 481-489.	1.7	203
13	Novel serologic biomarkers provide accurate estimates of recent <i>Plasmodium falciparum</i> exposure for individuals and communities. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4438-47.	3.3	188
14	Cysteine Proteases of Malaria Parasites: Targets for Chemotherapy. Current Pharmaceutical Design, 2002, 8, 1659-1672.	0.9	182
15	Malaria in Uganda: Challenges to control on the long road to elimination. Acta Tropica, 2012, 121, 184-195.	0.9	181
16	Antimalarial drug discovery: old and new approaches. Journal of Experimental Biology, 2003, 206, 3735-3744.	0.8	178
17	Antimalarial drug resistance in Africa: the calm before the storm?. Lancet Infectious Diseases, The, 2019, 19, e338-e351.	4.6	167
18	Malaria Transmission, Infection, and Disease at Three Sites with Varied Transmission Intensity in Uganda: Implications for Malaria Control. American Journal of Tropical Medicine and Hygiene, 2015, 92, 903-912.	0.6	157

#	Article	IF	Citations
19	Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorganic and Medicinal Chemistry, 1999, 7, 633-638.	1.4	156
20	Combination Therapy for Uncomplicated Falciparum Malaria in Ugandan Children. JAMA - Journal of the American Medical Association, 2007, 297, 2210.	3.8	155
21	Artesunate for the Treatment of Severe Falciparum Malaria. New England Journal of Medicine, 2008, 358, 1829-1836.	13.9	154
22	Polymorphisms in thePlasmodium falciparum pfcrtandpfmdrâ€1Genes and Clinical Response to Chloroquine in Kampala, Uganda. Journal of Infectious Diseases, 2001, 183, 1417-1420.	1.9	152
23	Structures of Falcipain-2 and Falcipain-3 Bound to Small Molecule Inhibitors: Implications for Substrate Specificity. Journal of Medicinal Chemistry, 2009, 52, 852-857.	2.9	148
24	Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. Molecular and Biochemical Parasitology, 2006, 150, 96-106.	0.5	144
25	Selection of Plasmodium falciparum pfmdr1 Alleles following Therapy with Artemether-Lumefantrine in an Area of Uganda where Malaria Is Highly Endemic. Antimicrobial Agents and Chemotherapy, 2006, 50, 1893-1895.	1.4	143
26	A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes. PLoS ONE, 2008, 3, e2252.	1.1	139
27	Antimalarial Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrobial Agents and Chemotherapy, 2005, 49, 2983-2985.	1.4	137
28	Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial. PLOS Clinical Trials, 2007, 2, e20.	3.5	128
29	Rapid Diagnostic Tests for Malaria at Sites of Varying Transmission Intensity in Uganda. Journal of Infectious Diseases, 2008, 197, 510-518.	1.9	128
30	Antimalarial Synergy of Cysteine and Aspartic Protease Inhibitors. Antimicrobial Agents and Chemotherapy, 1998, 42, 2254-2258.	1.4	123
31	Prolonged Selection of pfmdr1 Polymorphisms After Treatment of Falciparum Malaria With Artemether-Lumefantrine in Uganda. Journal of Infectious Diseases, 2011, 204, 1120-1124.	1.9	122
32	The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9138-9143.	3.3	121
33	Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in Uganda. PLoS ONE, 2008, 3, e2390.	1.1	120
34	Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8721-8726.	3.3	117
35	Falcipains and Other Cysteine Proteases of Malaria Parasites. Advances in Experimental Medicine and Biology, 2011, 712, 30-48.	0.8	116
36	Plasmodium Food Vacuole Plasmepsins Are Activated by Falcipains. Journal of Biological Chemistry, 2008, 283, 12870-12876.	1.6	113

#	Article	IF	Citations
37	Measures of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor Residual Spraying at Three Sites in Uganda: A Prospective Observational Study. PLoS Medicine, 2016, 13, e1002167.	3.9	111
38	Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda. Journal of Infectious Diseases, 2021, 223, 985-994.	1.9	111
39	A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nature Communications, 2017, 8, 14574.	5.8	110
40	The interplay between drug resistance and fitness in malaria parasites. Molecular Microbiology, 2013, 89, 1025-1038.	1.2	109
41	Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet, The, 2007, 369, 491-498.	6.3	108
42	Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso. Clinical Infectious Diseases, 2007, 45, 1453-1461.	2.9	108
43	Isolation and characterization of a cysteine proteinase gene of Plasmodium falciparum. Molecular and Biochemical Parasitology, 1992, 51, 143-152.	0.5	104
44	Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria in Uganda. PLOS Clinical Trials, 2006, 1, e7.	3.5	104
45	Cysteine proteases in protozoan parasites. PLoS Neglected Tropical Diseases, 2018, 12, e0006512.	1.3	104
46	Falcipain Inhibitors: Optimization Studies of the 2-Pyrimidinecarbonitrile Lead Series. Journal of Medicinal Chemistry, 2010, 53, 6129-6152.	2.9	102
47	Polymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan Children. PLoS ONE, 2014, 9, e105690.	1.1	101
48	Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11503-11508.	3.3	96
49	Hydrolysis of erythrocyte proteins by proteases of malaria parasites. Current Opinion in Hematology, 2002, 9, 140-145.	1.2	95
50	Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan Children. New England Journal of Medicine, 2012, 367, 2110-2118.	13.9	95
51	Artemisinin versus Nonartemisinin Combination Therapy for Uncomplicated Malaria: Randomized Clinical Trials from Four Sites in Uganda. PLoS Medicine, 2005, 2, e190.	3.9	94
52	Selection of Known <i>Plasmodium falciparum</i> Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin-Piperaquine in Burkina Faso. Antimicrobial Agents and Chemotherapy, 2010, 54, 1949-1954.	1.4	91
53	Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study. Lancet Infectious Diseases, The, 2021, 21, 1568-1578.	4.6	90
54	VALIDATION OF MICROSATELLITE MARKERS FOR USE IN GENOTYPING POLYCLONAL PLASMODIUM FALCIPARUM INFECTIONS. American Journal of Tropical Medicine and Hygiene, 2006, 75, 836-842.	0.6	86

#	Article	IF	Citations
55	Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. ELife, 2021, 10, .	2.8	85
56	Comparative Impacts Over 5 Years of Artemisinin-Based Combination Therapies on Plasmodium falciparum Polymorphisms That Modulate Drug Sensitivity in Ugandan Children. Journal of Infectious Diseases, 2014, 210, 344-353.	1.9	84
57	Recombinant falcipain-2 cleaves erythrocyte membrane ankyrin and protein 4.1. Molecular and Biochemical Parasitology, 2001, 116, 95-99.	0.5	83
58	Impact of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine on Malaria in Ugandan Schoolchildren: A Randomized, Placebo-Controlled Trial. Clinical Infectious Diseases, 2014, 58, 1404-1412.	2.9	83
59	Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ: British Medical Journal, 2009, 339, b2763-b2763.	2.4	82
60	Falstatin, a Cysteine Protease Inhibitor of Plasmodium falciparum, Facilitates Erythrocyte Invasion. PLoS Pathogens, 2006, 2, e117.	2.1	80
61	Protective Efficacy and Safety of Three Antimalarial Regimens for the Prevention of Malaria in Young Ugandan Children: A Randomized Controlled Trial. PLoS Medicine, 2014, 11, e1001689.	3.9	79
62	Synthesis, Structure and in Vitro Biological Screening of Palladium(II) Complexes of Functionalised Salicylaldimine Thiosemicarbazones as Antimalarial and Anticancer Agents. European Journal of Inorganic Chemistry, 2010, 2010, 3520-3528.	1.0	78
63	COVID-19: Shining the Light on Africa. American Journal of Tropical Medicine and Hygiene, 2020, 102, 1145-1148.	0.6	78
64	Biosynthesis, localization, and processing of falcipain cysteine proteases of Plasmodium falciparum. Molecular and Biochemical Parasitology, 2005, 139, 205-212.	0.5	77
65	Geographic Differences in Antimalarial Drug Efficacy in Uganda Are Explained by Differences in Endemicity and Not by Known Molecular Markers of Drug Resistance. Journal of Infectious Diseases, 2006, 193, 978-986.	1.9	76
66	In Vitro Sensitivities of Plasmodium falciparum to Different Antimalarial Drugs in Uganda. Antimicrobial Agents and Chemotherapy, 2010, 54, 1200-1206.	1.4	72
67	Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6863-E6870.	3.3	71
68	Synthesis and structureâ€“activity relationships of novel benzoxaboroles as a new class of antimalarial agents. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 644-651.	1.0	69
69	Resistance-Mediating Plasmodium falciparum pfcrt and pfmdr1 Alleles after Treatment with Artesunate-Amodiaquine in Uganda. Antimicrobial Agents and Chemotherapy, 2007, 51, 3023-3025.	1.4	67
70	Discordant Patterns of Genetic Variation at Two Chloroquine Resistance Loci in Worldwide Populations of the Malaria Parasite <i>Plasmodium falciparum</i>. Antimicrobial Agents and Chemotherapy, 2008, 52, 2212-2222.	1.4	67
71	Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. American Journal of Tropical Medicine and Hygiene, 2006, 75, 836-42.	0.6	67
72	Metagenomic next-generation sequencing of samples from pediatric febrile illness in Tororo, Uganda. PLoS ONE, 2019, 14, e0218318.	1.1	66

#	Article	IF	Citations
73	Plasmodium falciparum: Biochemical characterization of the cysteine protease falcipain-2â€². Experimental Parasitology, 2006, 112, 187-192.	0.5	64
74	Probing the aurone scaffold against Plasmodium falciparum: Design, synthesis and antimalarial activity. European Journal of Medicinal Chemistry, 2014, 80, 523-534.	2.6	64
75	Identification and biochemical characterization of vivapains, cysteine proteases of the malaria parasite Plasmodium vivax. Biochemical Journal, 2004, 378, 529-538.	1.7	63
76	Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial. Journal of Infectious Diseases, 2016, 213, 1134-1142.	1.9	63
77	Targeting <i>Toxoplasma gondii</i> <scp>CPSF</scp> 3 as a new approach to control toxoplasmosis. EMBO Molecular Medicine, 2017, 9, 385-394.	3.3	61
78	1H-1,2,3-Triazole-tethered isatin-7-chloroquinoline and 3-hydroxy-indole-7-chloroquinoline conjugates: Synthesis and antimalarial evaluation. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 756-759.	1.0	60
79	4-Aminoquinoline-ferrocenyl-chalcone conjugates: Synthesis and anti-plasmodial evaluation. European Journal of Medicinal Chemistry, 2017, 125, 269-277.	2.6	60
80	Hemoglobin Cleavage Site-Specificity of the Plasmodium falciparum Cysteine Proteases Falcipain-2 and Falcipain-3. PLoS ONE, 2009, 4, e5156.	1.1	59
81	N-Cinnamoylated Chloroquine Analogues as Dual-Stage Antimalarial Leads. Journal of Medicinal Chemistry, 2013, 56, 556-567.	2.9	58
82	Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents and Chemotherapy, 2015, 59, 4387-4396.	1.4	58
83	Antimalarial Benzoxaboroles Target Plasmodium falciparum Leucyl-tRNA Synthetase. Antimicrobial Agents and Chemotherapy, 2016, 60, 4886-4895.	1.4	58
84	The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRC. Nature Communications, 2020, 11, 2107.	5.8	57
85	Temporal Changes in Prevalence of Molecular Markers Mediating Antimalarial Drug Resistance in a High Malaria Transmission Setting in Uganda. American Journal of Tropical Medicine and Hygiene, 2014, 91, 54-61.	0.6	56
86	Estimating malaria parasite prevalence from community surveys in Uganda: a comparison of microscopy, rapid diagnostic tests and polymerase chain reaction. Malaria Journal, 2015, 14, 528.	0.8	56
87	Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda Based on Parasitological and Molecular Assays. Antimicrobial Agents and Chemotherapy, 2015, 59, 5061-5064.	1.4	55
88	Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase. Antimicrobial Agents and Chemotherapy, 2016, 60, 5817-5827.	1.4	55
89	Independent Intramolecular Mediators of Folding, Activity, and Inhibition for the Plasmodium falciparum Cysteine Protease Falcipain-2. Journal of Biological Chemistry, 2004, 279, 3484-3491.	1.6	53
90	Folding of the Plasmodium falciparum Cysteine Protease Falcipain-2 Is Mediated by a Chaperone-like Peptide and Not the Prodomain. Journal of Biological Chemistry, 2002, 277, 14910-14915.	1.6	52

#	Article	IF	Citations
91	Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate. Journal of Medicinal Chemistry, 2017, 60, 5889-5908.	2.9	52
92	Changing Antimalarial Drug Sensitivities in Uganda. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	52
93	Impact of Antimalarial Treatment and Chemoprevention on the Drug Sensitivity of Malaria Parasites Isolated from Ugandan Children. Antimicrobial Agents and Chemotherapy, 2015, 59, 3018-3030.	1.4	48
94	Plasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene. Malaria Journal, 2010, 9, 174.	0.8	47
95	Synthesis of Gallinamide A Analogues as Potent Falcipain Inhibitors and Antimalarials. Journal of Medicinal Chemistry, 2014, 57, 10557-10563.	2.9	47
96	4-Aminoquinoline-chalcone/- N -acetylpyrazoline conjugates: Synthesis and antiplasmodial evaluation. European Journal of Medicinal Chemistry, 2017, 138, 993-1001.	2.6	47
97	PRINCIPAL ROLE OF DIHYDROPTEROATE SYNTHASE MUTATIONS IN MEDIATING RESISTANCE TO SULFADOXINE-PYRIMETHAMINE IN SINGLE-DRUG AND COMBINATION THERAPY OF UNCOMPLICATED MALARIA IN UGANDA. American Journal of Tropical Medicine and Hygiene, 2004, 71, 758-763.	0.6	47
98	Regulatory Elements within the Prodomain of Falcipain-2, a Cysteine Protease of the Malaria Parasite Plasmodium falciparum. PLoS ONE, 2009, 4, e5694.	1.1	46
99	Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs). Journal of Medicinal Chemistry, 2017, 60, 6911-6923.	2.9	46
100	Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries. JAMA Pediatrics, 2022, 176, e216436.	3.3	44
101	Synthesis and structureâ€“activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the Plasmodium falciparum cysteine protease falcipain-2. European Journal of Medicinal Chemistry, 2015, 90, 507-518.	2.6	43
102	Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. Nature Communications, 2019, 10, 2816.	5.8	43
103	Synthesis and inÂvitro antiplasmodial evaluation of 7-chloroquinolineâ€“chalcone and 7-chloroquinolineâ€“ferrocenylchalcone conjugates. European Journal of Medicinal Chemistry, 2015, 95, 230-239.	2.6	42
104	Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents and Chemotherapy, 2014, 58, 3660-3665.	1.4	41
105	The Effect of Storage and Extraction Methods on Amplification of Plasmodium falciparum DNA from Dried Blood Spots. American Journal of Tropical Medicine and Hygiene, 2015, 92, 922-925.	0.6	41
106	Changing antimalarial drug resistance patterns identified by surveillance at three sites in Uganda. Journal of Infectious Diseases, 2017, 215, jiw614.	1.9	41
107	Falcipain Cysteine Proteases Require Bipartite Motifs for Trafficking to the Plasmodium falciparum Food Vacuole*. Journal of Biological Chemistry, 2007, 282, 24961-24969.	1.6	40
108	Novel Endoperoxide-Based Transmission-Blocking Antimalarials with Liver- and Blood-Schizontocidal Activities. ACS Medicinal Chemistry Letters, 2014, 5, 108-112.	1.3	40

#	Article	IF	Citations
109	Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	39
110	Critical role of amino acid 23 in mediating activity and specificity of vinckepain-2, a papain-family cysteine protease of rodent malaria parasites. Biochemical Journal, 2002, 368, 273-281.	1.7	38
111	Characterizing microscopic and submicroscopic malaria parasitaemia at three sites with varied transmission intensity in Uganda. Malaria Journal, 2016, 15, 470.	0.8	38
112	Point of Care Testing for Malaria Using LAMP, Loop Mediated Isothermal Amplification. Journal of Infectious Diseases, 2014, 210, 1167-1169.	1.9	37
113	Optimization of a Ligase Detection Reaction-Fluorescent Microsphere Assay for Characterization of Resistance-Mediating Polymorphisms in African Samples of Plasmodium falciparum. Journal of Clinical Microbiology, 2013, 51, 2564-2570.	1.8	36
114	Perspectives on Battling COVID-19 in Countries of Latin America and the Caribbean. American Journal of Tropical Medicine and Hygiene, 2020, 103, 593-596.	0.6	36
115	Imidazoquines as Antimalarial and Antipneumocystis Agents. Journal of Medicinal Chemistry, 2009, 52, 7800-7807.	2.9	35
116	PRIMACINS, N-cinnamoyl-primaquine conjugates, with improved liver-stage antimalarial activity. MedChemComm, 2012, 3, 1170.	3.5	35
117	Demographic, Socioeconomic, and Geographic Factors Leading to Severe Malaria and Delayed Care Seeking in Ugandan Children: A Caseâ€"Control Study. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1513-1523.	0.6	35
118	Squaric acid: a valuable scaffold for developing antimalarials?. MedChemComm, 2012, 3, 489.	3.5	34
119	Longitudinal Outcomes in a Cohort of Ugandan Children Randomized to Artemether-Lumefantrine Versus Dihydroartemisinin-Piperaquine for the Treatment of Malaria. Clinical Infectious Diseases, 2014, 59, 509-516.	2.9	34
120	Urea/oxalamide tethered Î2-lactam-7-chloroquinoline conjugates: Synthesis and inÂvitro antimalarial evaluation. European Journal of Medicinal Chemistry, 2014, 71, 128-134.	2.6	34
121	Drug susceptibility of Plasmodium falciparum in eastern Uganda: a longitudinal phenotypic and genotypic study. Lancet Microbe, The, 2021, 2, e441-e449.	3.4	34
122	Design, synthesis and evaluation of 3-methylene-substituted indolinones as antimalarials. European Journal of Medicinal Chemistry, 2011, 46, 927-933.	2.6	33
123	Selection of Cysteine Protease Inhibitor-resistant Malaria Parasites Is Accompanied by Amplification of Falcipain Genes and Alteration in Inhibitor Transport. Journal of Biological Chemistry, 2004, 279, 35236-35241.	1.6	32
124	Novel Potent Metallocenes against Liver Stage Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 1564-1570.	1.4	32
125	Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2<i>R</i>,3<i>S</i>)-<i>N</i>-Benzoyl-3-phenylisoserine. ACS Medicinal Chemistry Letters, 2013, 4, 637-641.	1.3	32
126	Plasmodium falciparum Falcipain-2a Polymorphisms in Southeast Asia and Their Association With Artemisinin Resistance. Journal of Infectious Diseases, 2018, 218, 434-442.	1.9	32

#	Article	IF	Citations
127	Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: A cluster-randomized, placebo-controlled trial. PLoS Medicine, 2019, 16, e1002835.	3.9	32
128	Falcipain cysteine proteases of malaria parasites: An update. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140362.	1.1	32
129	Plasmodium Species Infecting Children Presenting with Malaria in Uganda. American Journal of Tropical Medicine and Hygiene, 2017, 97, 753-757.	0.6	32
130	Benzoxaborole Antimalarial Agents. Part 4. Discovery of Potent 6-(2-(Alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles. Journal of Medicinal Chemistry, 2015, 58, 5344-5354.	2.9	31
131	Azithromycin for Malaria?. American Journal of Tropical Medicine and Hygiene, 2016, 95, 2-4.	0.6	31
132	Synthesis, anti-plasmodial and cytotoxic evaluation of 1H-1,2,3-triazole/acyl hydrazide integrated tetrahydro-Î²-carboline-4-aminoquinoline conjugates. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126810.	1.0	31
133	The Importance of Diagnostic Testing during a Viral Pandemic: Early Lessons from Novel Coronavirus Disease (COVID-19). American Journal of Tropical Medicine and Hygiene, 2020, 102, 915-916.	0.6	31
134	Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. American Journal of Tropical Medicine and Hygiene, 2004, 71, 758-63.	0.6	31
135	Selection of Parasites with Diminished Drug Susceptibility by Amodiaquineâ€Containing Antimalarial Regimens in Uganda. Journal of Infectious Diseases, 2009, 200, 1650-1657.	1.9	30
136	1,4-Naphthoquinone Cations as Antiplasmodial Agents: Hydroxy-, Acyloxy-, and Alkoxy-Substituted Analogues. ACS Medicinal Chemistry Letters, 2012, 3, 1029-1033.	1.3	30
137	Enantiopure Indolizinoindolones with in vitro Activity against Bloodâ€•and Liverâ€Stage Malaria Parasites. ChemMedChem, 2015, 10, 2080-2089.	1.6	30
138	Endoperoxide-8-aminoquinoline hybrids as dual-stage antimalarial agents with enhanced metabolic stability. European Journal of Medicinal Chemistry, 2018, 149, 69-78.	2.6	30
139	Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children. Journal of Infectious Diseases, 2019, 219, 1112-1120.	1.9	30
140	Discovery of highly selective 7-chloroquinoline-thiohydantoins with potent antimalarial activity. European Journal of Medicinal Chemistry, 2014, 84, 425-432.	2.6	29
141	Î²-amino-alcohol tethered 4-aminoquinoline-isatin conjugates: Synthesis and antimalarial evaluation. European Journal of Medicinal Chemistry, 2014, 84, 566-573.	2.6	28
142	Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Plasmodium Falciparum Drug Sensitivity-Associated Haplotypes in Uganda. Open Forum Infectious Diseases, 2017, 4, ofw229.	0.4	28
143	Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. Nature Communications, 2019, 10, 480.	5.8	28
144	Improvement of Asparagine Ethylenediamines as Anti-malarial <i>Plasmodium</i>-Selective Proteasome Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 6137-6145.	2.9	28

#	Article	IF	Citations
145	Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LCâ€“MS/MS. Bioanalysis, 2014, 6, 3081-3089.	0.6	27
146	Characterization of a Plasmodium vivax Cysteine Proteinase Gene Identifies Uniquely Conserved Amino Acids that May Mediate the Substrate Specificity of Malarial Hemoglobinases. Journal of Molecular Biology, 1994, 241, 312-316.	2.0	26
147	Microwave-promoted facile access to 4-aminoquinoline-phthalimides: Synthesis and anti-plasmodial evaluation. European Journal of Medicinal Chemistry, 2018, 143, 150-156.	2.6	26
148	Falcipain Inhibitors Based on the Natural Product Gallinamide A Are Potent in Vitro and in Vivo Antimalarials. Journal of Medicinal Chemistry, 2019, 62, 5562-5578.	2.9	26
149	PRIMACENES: novel non-cytotoxic primaquine-ferrocene conjugates with anti-Pneumocystis carinii activity. MedChemComm, 2010, 1, 199.	3.5	25
150	Limited Ability of <i>Plasmodium falciparum pfcrt</i> , <i>pfmdr1</i> , and <i>pfnhe1</i> Polymorphisms To Predict Quinine <i>In Vitro</i> Sensitivity or Clinical Effectiveness in Uganda. Antimicrobial Agents and Chemotherapy, 2011, 55, 615-622.	1.4	25
151	Synthesis, Antiplasmodial Activity, and Î²-Hematin Inhibition of Hydroxypyridoneâ€“Chloroquine Hybrids. ACS Medicinal Chemistry Letters, 2013, 4, 642-646.	1.3	25
152	Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda. Malaria Journal, 2014, 13, 95.	0.8	25
153	Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity. Antimicrobial Agents and Chemotherapy, 2016, 60, 5649-5654.	1.4	25
154	Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistanceâ€“Mediating Polymorphisms in Uganda. Journal of Infectious Diseases, 2017, 216, 1008-1017.	1.9	25
155	The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance. Science Translational Medicine, 2021, 13, .	5.8	25
156	Complexity of<i>Plasmodium falciparum</i>Clinical Samples from Uganda during Shortâ€Term Culture. Journal of Infectious Diseases, 2008, 198, 1554-1557.	1.9	24
157	Biochemical Properties of a Novel Cysteine Protease of Plasmodium vivax, Vivapain-4. PLoS Neglected Tropical Diseases, 2010, 4, e849.	1.3	24
158	Differential Prevalence of Transporter Polymorphisms in Symptomatic and Asymptomatic Falciparum Malaria Infections in Uganda. Journal of Infectious Diseases, 2014, 210, 154-157.	1.9	24
159	Molecular assays for antimalarial drug resistance surveillance: A target product profile. PLoS ONE, 2018, 13, e0204347.	1.1	24
160	Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series. Journal of Medicinal Chemistry, 2021, 64, 6085-6136.	2.9	24
161	Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors. MedChemComm, 2011, 2, 1201.	3.5	23
162	Probing the Azaaurone Scaffold against the Hepatic and Erythrocytic Stages of Malaria Parasites. ChemMedChem, 2016, 11, 2194-2204.	1.6	23

#	Article	IF	Citations
163	The Relative Effects of Artemether-lumefantrine and Non-artemisinin Antimalarials on Gametocyte Carriage and Transmission of Plasmodium falciparum: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2017, 65, 486-494.	2.9	22
164	Understanding the context of delays in seeking appropriate care for children with symptoms of severe malaria in Uganda. PLoS ONE, 2019, 14, e0217262.	1.1	22
165	Persistent Parasitemia Despite Dramatic Reduction in Malaria Incidence After 3 Rounds of Indoor Residual Spraying in Tororo, Uganda. Journal of Infectious Diseases, 2019, 219, 1104-1111.	1.9	22
166	Stage-Specific Antimalarial Activity of Cysteine Protease Inhibitors. Biological Chemistry, 2002, 383, 843-7.	1.2	21
167	Artefenomel: a promising new antimalarial drug. Lancet Infectious Diseases, The, 2016, 16, 6-8.	4.6	21
168	Clinical consequences of submicroscopic malaria parasitaemia in Uganda. Malaria Journal, 2018, 17, 67.	0.8	21
169	Functionalized Naphthalimide-4-aminoquinoline Conjugates as Promising Antiplasmodials, with Mechanistic Insights. ACS Medicinal Chemistry Letters, 2020, 11, 154-161.	1.3	21
170	Has artemisinin resistance emerged in Africa?. Lancet Infectious Diseases, The, 2021, 21, 1056-1057.	4.6	21
171	Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda. Malaria Journal, 2017, 16, 67.	0.8	20
172	Malaria: How Are We Doing and How Can We Do Better?. American Journal of Tropical Medicine and Hygiene, 2019, 100, 239-241.	0.6	20
173	Development of a Highly Selective <i>Plasmodium falciparum</i> Proteasome Inhibitor with Antiâ€malaria Activity in Humanized Mice. Angewandte Chemie - International Edition, 2021, 60, 9279-9283.	7.2	20
174	Design, Synthesis and Evaluation of Trisubstituted Thiazoles Targeting Plasmodium Falciparum Cysteine Proteases. Medicinal Chemistry Research, 2005, 14, 74-105.	1.1	19
175	Fitness Consequences of <i>Plasmodium falciparum pfmdr1</i> Polymorphisms Inferred from <i>Ex Vivo</i> Culture of Ugandan Parasites. Antimicrobial Agents and Chemotherapy, 2013, 57, 4245-4251.	1.4	19
176	Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clinical Infectious Diseases, 2018, 67, 1079-1088.	2.9	19
177	Antimalarial Trioxolanes with Superior Drug-Like Properties and In Vivo Efficacy. ACS Infectious Diseases, 2020, 6, 1827-1835.	1.8	19
178	Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation. MBio, 2020, 11, .	1.8	19
179	Synthesis and in Vitro and in Vivo Pharmacological Evaluation of New 4-Aminoquinoline-Based Compounds. ACS Medicinal Chemistry Letters, 2013, 4, 1198-1202.	1.3	18
180	Piperazineâ€linked 4â€aminoquinolineâ€chalcone/ferrocenylâ€chalcone conjugates: Synthesis and antiplasmodial evaluation. Chemical Biology and Drug Design, 2017, 90, 590-595.	1.5	18

#	Article	IF	Citations
181	Artemisinin-Based Combination Therapies Are Efficacious and Safe for Treatment of Uncomplicated Malaria in HIV-Infected Ugandan Children. Clinical Infectious Diseases, 2014, 59, 446-453.	2.9	17
182	Novel squaramides with in vitro liver stage antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2016, 24, 1786-1792.	1.4	17
183	Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine. PLoS ONE, 2014, 9, e103200.	1.1	16
184	Synthesis, biological evaluation, hydration site thermodynamics, and chemical reactivity analysis of Î±-keto substituted peptidomimetics for the inhibition of Plasmodium falciparum. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1274-1279.	1.0	16
185	Performance of Loop-Mediated Isothermal Amplification for the Identification of Submicroscopic Plasmodium falciparum Infection in Uganda. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1777-1781.	0.6	16
186	N10,N11-di-alkylamine indolo[3,2-b]quinolines as hemozoin inhibitors: Design, synthesis and antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2015, 23, 1530-1539.	1.4	15
187	Coupling the Antimalarial Cell Penetrating Peptide TP10 to Classical Antimalarial Drugs Primaquine and Chloroquine Produces Strongly Hemolytic Conjugates. Molecules, 2019, 24, 4559.	1.7	14
188	Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	14
189	A trio of quinoline-isoniazid-phthalimide with promising antiplasmodial potential: Synthesis, in-vitro evaluation and heme-polymerization inhibition studies. Bioorganic and Medicinal Chemistry, 2021, 39, 116159.	1.4	14
190	Artemisinin Resistance Outside of Southeast Asia. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1357-1359.	0.6	14
191	The Impact of Control Interventions on Malaria Burden in Young Children in a Historically High-Transmission District of Uganda: A Pooled Analysis of Cohort Studies from 2007 to 2018. American Journal of Tropical Medicine and Hygiene, 2020, 103, 785-792.	0.6	14
192	Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria. Journal of Medicinal Chemistry, 2022, 65, 3798-3813.	2.9	14
193	Allosteric regulation of the Plasmodium falciparum cysteine protease falcipain-2 by heme. Archives of Biochemistry and Biophysics, 2015, 573, 92-99.	1.4	13
194	Marked variation in prevalence of malaria-protective human genetic polymorphisms across Uganda. Infection, Genetics and Evolution, 2017, 55, 281-287.	1.0	13
195	Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virusâ€"Infected Women Receiving Efavirenz. Journal of Infectious Diseases, 2018, 217, 964-972.	1.9	13
196	Substituted 1,3-dioxoisoindoline-4-aminoquinolines coupled via amide linkers: Synthesis, antiplasmodial and cytotoxic evaluation. Bioorganic Chemistry, 2019, 88, 102912.	2.0	13
197	Design, synthesis, crystal structure and anti-plasmodial evaluation of tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidine derivatives. RSC Medicinal Chemistry, 2021, 12, 970-981.	1.7	13
198	Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183. Nature Communications, 2022, 13, 2158.	5.8	13

#	Article	IF	Citations
199	Association Between Recent Overnight Travel and Risk of Malaria: A Prospective Cohort Study at 3 Sites in Uganda. Clinical Infectious Diseases, 2019, 68, 313-320.	2.9	12
200	Design, synthesis, heme binding and density functional theory studies of isoindoline-dione-4-aminoquinolines as potential antiplasmodials. Future Medicinal Chemistry, 2020, 12, 193-205.	1.1	12
201	Are three drugs for malaria better than two?. Lancet, The, 2020, 395, 1316-1317.	6.3	12
202	Exploring the Molecular Basis of Q_o<i>bc</i>₁ Complex Inhibitors Activity to Find Novel Antimalarials Hits. Molecular Informatics, 2013, 32, 659-670.	1.4	11
203	Resistance to Some But Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a <i>Plasmodium falciparum</i> Esterase. ACS Infectious Diseases, 2020, 6, 2994-3003.	1.8	11
204	Artemisinin resistance in Africa: How urgent is the threat?. Med, 2021, 2, 1287-1288.	2.2	11
205	Associations between Malaria-Preventive Regimens and Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Ugandan Pregnant Women. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	10
206	Are Artemisinin-Based Combination Therapies For Malaria Beginning To Fail in Africa?. American Journal of Tropical Medicine and Hygiene, 2021, 105, 857-858.	0.6	10
207	Mass Azithromycin and Malaria Parasitemia in Niger: Results from a Community-Randomized Trial. American Journal of Tropical Medicine and Hygiene, 2017, 97, 696-701.	0.6	10
208	Cross-Talk between Malarial Cysteine Proteases and Falstatin: The BC Loop as a Hot-Spot Target. PLoS ONE, 2014, 9, e93008.	1.1	9
209	Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in <i>pfmdr1</i>. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	9
210	Caregiver responses and association with delayed care-seeking in children with uncomplicated and severe malaria. Malaria Journal, 2018, 17, 476.	0.8	9
211	Associations between erythrocyte polymorphisms and risks of uncomplicated and severe malaria in Ugandan children: A case control study. PLoS ONE, 2018, 13, e0203229.	1.1	9
212	The Diversity of the <i>Plasmodium falciparum</i> K13 Propeller Domain Did Not Increase after Implementation of Artemisinin-Based Combination Therapy in Uganda. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	9
213	Comparative Prevalence of Plasmodium falciparum Resistance-Associated Genetic Polymorphisms in Parasites Infecting Humans and Mosquitoes in Uganda. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1576-1580.	0.6	9
214	Malaria Diagnosed in an Urban Setting Strongly Associated with Recent Overnight Travel: A Caseâ€“Control Study from Kampala, Uganda. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1517-1524.	0.6	9
215	Discovery of spirooxadiazoline oxindoles with dual-stage antimalarial activity. European Journal of Medicinal Chemistry, 2022, 236, 114324.	2.6	9
216	Associations between red blood cell variants and malaria among children and adults from three areas of Uganda: a prospective cohort study. Malaria Journal, 2020, 19, 21.	0.8	8

#	Article	IF	Citations
217	Impact of a Rapid Decline in Malaria Transmission on Antimalarial IgG Subclasses and Avidity. Frontiers in Immunology, 2020, 11, 576663.	2.2	8
218	Comparative Analysis of Plasmodium falciparum Genotyping via SNP Detection, Microsatellite Profiling, and Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0116321.	1.4	8
219	Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women. Clinical Infectious Diseases, 2022, 75, 406-415.	2.9	8
220	Malaria parasites fine-tune mutations to resist drugs. Nature, 2019, 576, 217-219.	13.7	7
221	Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials. Journal of Medicinal Chemistry, 2020, 63, 6179-6202.	2.9	7
222	Proteases and Hemoglobin Degradation. , 0, , 311-326.		7
223	Artemisinin Resistance in Eastern India. Clinical Infectious Diseases, 2019, 69, 1153-1155.	2.9	6
224	Biannual versus annual mass azithromycin distribution and malaria seroepidemiology among preschool children in Niger: a sub-study of a cluster randomized trial. Malaria Journal, 2019, 18, 389.	0.8	6
225	Association between recent overnight travel and use of long-lasting insecticidal nets in rural Uganda: a prospective cohort study in Tororo. Malaria Journal, 2020, 19, 405.	0.8	6
226	Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations. PLoS ONE, 2020, 15, e0233893.	1.1	6
227	Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children. Nature Communications, 2021, 12, 6714.	5.8	6
228	Drug resistance mediating Plasmodium falciparum polymorphisms and clinical presentations of parasitaemic children in Uganda. Malaria Journal, 2017, 16, 125.	0.8	5
229	Diversity of KIR genes and their HLA-C ligands in Ugandan populations with historically varied malaria transmission intensity. Malaria Journal, 2021, 20, 111.	0.8	5
230	Balanced impacts of fitness and drug pressure on the evolution of PfMDR1 polymorphisms in Plasmodium falciparum. Malaria Journal, 2021, 20, 292.	0.8	5
231	Decreased Susceptibility to Dihydrofolate Reductase Inhibitors Associated With Genetic Polymorphisms in Ugandan <i>Plasmodium falciparum</i> Isolates. Journal of Infectious Diseases, 2022, 225, 696-704.	1.9	5
232	Distinct Biomarker Profiles Distinguish Malawian Children with Malarial and Non-malarial Sepsis. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1424-1433.	0.6	5
233	Expanded Availability of Intravenous Artesunate for the Treatment of Severe Malaria in the United States. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1295-1296.	0.6	5
234	Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisininâ€Piperaquine as Malaria Chemoprevention. Clinical Pharmacology and Therapeutics, 2019, 106, 1310-1318.	2.3	4

#	Article	IF	Citations
235	Amalgamating Isatin/Indole/Nitroimidazole with 7â€chloroquinolines <i>via</i> azideâ€alkyne cycloaddition: Synthesis, antiâ€plasmodial, and cytotoxic evaluation. Chemical Biology and Drug Design, 2020, 96, 1355-1361.	1.5	4
236	Withinâ€household clustering of genetically related Plasmodium falciparum infections in a moderate transmission area of Uganda. Malaria Journal, 2021, 20, 68.	0.8	4
237	Deletions of pfhrp2 and pfhrp3 genes were uncommon in rapid diagnostic test-negative Plasmodium falciparum isolates from Uganda. Malaria Journal, 2021, 20, 4.	0.8	4
238	Prophylaxis and treatment of malaria in HIV-infected populations. Future HIV Therapy, 2008, 2, 453-464.	0.5	3
239	Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	3
240	Associations between Aminoquinoline Resistance Genotypes and Clinical Presentations of Plasmodium falciparum Infection in Uganda. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	3
241	Novel 1,2,3-triazole <i>epicinchonas</i>: Transitioning from organocatalysis to biological activities. Synthetic Communications, 2021, 51, 2954-2974.	1.1	3
242	Identification, Characterization, and Synthesis of Natural Parasitic Cysteine Protease Inhibitors: Pentacitidins Are More Potent Falcitidin Analogues. ACS Chemical Biology, 2022, 17, 576-589.	1.6	3
243	Functionalized 3-hydroxy-3-aminoquinoline-oxindole hybrids as promising dual-function anti-plasmodials. European Journal of Medicinal Chemistry Reports, 2022, 5, 100052.	0.6	3
244	The RTS,S/AS01 vaccine continues to show modest protection against malaria in African infants and children. Evidence-Based Medicine, 2015, 20, 179-179.	0.6	2
245	Mass Drug Administration to Control and Eliminate Malaria in Africa: How Do We Best Utilize the Tools at Hand?. Clinical Infectious Diseases, 2019, 69, 287-289.	2.9	2
246	Associations between Varied Susceptibilities to PfATP4 Inhibitors and Genotypes in Ugandan Plasmodium falciparum Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, e0077121.	1.4	2
247	Keep Politics out of Funding Decisions for Medical Research and Public Health. American Journal of Tropical Medicine and Hygiene, 2020, 103, 931-932.	0.6	2
248	Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography Open, 2022, 2, 100042.	0.8	2
249	Reply to Goyal et al. Journal of Infectious Diseases, 2015, 211, 1687-1687.	1.9	1
250	Long-chain alkyl-substituted gentisic acid and benzoquinone derivatives from the root of <i>Micronychia tsiramiramy</i> (Anacardiaceae). Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2016, 71, 297-303.	0.3	1
251	A shorter course for anti-relapse therapy against vivax malaria. Lancet, The, 2019, 394, 898-900.	6.3	1
252	The (International) American Society of Tropical Medicine and Hygiene. American Journal of Tropical Medicine and Hygiene, 2016, 95, 980-982.	0.6	1

#	Article	IF	Citations
253	Be Careful What You Eat!. American Journal of Tropical Medicine and Hygiene, 2019, 101, 955-956.	0.6	1
254	Impact of Short-Term Storage on <i>Ex Vivo</i> Antimalarial Susceptibilities of Fresh Ugandan Plasmodium falciparum Isolates. Antimicrobial Agents and Chemotherapy, 2022, 66, e0143721.	1.4	1
255	Back Cover: Cinnamic Acid/Chloroquinoline Conjugates as Potent Agents against Chloroquine-Resistant Plasmodium falciparum (ChemMedChem 9/2012). ChemMedChem, 2012, 7, 1692-1692.	1.6	0
256	Prevalence of Malaria Parasite Infections among U.S.-Bound Congolese Refugees with and without Splenomegaly. American Journal of Tropical Medicine and Hygiene, 2021, 104, 996-999.	0.6	0
257	Communicable Diseases: A Global Perspective. American Journal of Tropical Medicine and Hygiene, 2016, 95, 974-975.	0.6	0
258	â€œThe Way We Wereâ€•Ken Warrenâ€™s Legacy and Modern Investments in Global Health. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1955-1957.	0.6	0
259	[(7-chloroquinolin-4-yl)amino]acetophenones and their copper(II) derivatives: Synthesis, characterization, computational studies and antimalarial activity. EXCLI Journal, 2019, 18, 962-987.	0.5	0
260	Title is missing!. , 2020, 15, e0233893.		0
261	Title is missing!. , 2020, 15, e0233893.		0
262	Title is missing!. , 2020, 15, e0233893.		0
263	Title is missing!. , 2020, 15, e0233893.		0
264	Title is missing!. , 2020, 15, e0233893.		0
265	Title is missing!. , 2020, 15, e0233893.		0